PRP can help some concerns, but there is no single answer to whether it works. The result depends on the diagnosis, the preparation, what it is compared with and the outcome being measured. Evidence for increased hair density cannot establish benefit for a painful tendon, skin concern or arthritic joint.
For someone considering PRP in London, a useful assessment connects the research with their own concern and the alternatives. At The London PRP Clinic by The Wellness, an enquiry can begin with that discussion, rather than a commitment to a course of injections.
Why the comparison matters
Platelet-rich plasma is prepared from a person's own blood. It contains platelets and substances involved in tissue repair. That biological explanation is a reason to study it, not proof that an injection will produce a worthwhile clinical benefit.
A study may compare PRP with saline, a steroid injection, another treatment or the person's condition before treatment. These answer different questions. Improvement from the starting point does not establish that PRP caused it. A better result than steroid at one follow-up does not establish a better result than placebo or rehabilitation.
Discuss the evidence for your concern or email team@thewellnesslondon.com.
Pattern hair loss: evidence of increased density, with limits
A 2025 review in Dermatology and Therapy included 43 randomised trials involving 1,877 people with several types of alopecia. Its hair-density analysis, involving androgenetic or pattern hair loss, found a benefit compared with placebo. Results varied substantially between studies, and hair thickness did not show a significant overall improvement.
Two details affect treatment planning. The review did not find a significant association between treatment frequency and the hair-density effect. Its pooled comparison of PRP plus minoxidil with minoxidil alone also did not show a statistically significant additional density benefit. Those findings do not prove that schedules or combinations never matter; they mean this review cannot justify a universal claim that more frequent injections or combined treatment work better.
The diagnosis remains important. Pattern thinning, temporary shedding and inflammatory or scarring hair loss are not interchangeable. The British Association of Dermatologists' guidance explains diagnosis and established options for female pattern hair loss. A plan should place PRP alongside appropriate alternatives, with a review point and a realistic account of uncertainty.
Tennis elbow: steroid comparisons and placebo findings differ
A 2025 review of 26 randomised trials involving 1,877 people compared PRP with corticosteroid injections. Steroid performed better for short-term pain, while PRP performed better for pain beyond six months. The long-term functional difference was statistically significant but below the review's threshold for clinical importance.
A 2026 meta-analysis of placebo-controlled trials reached a different, directly relevant conclusion. Across six trials involving 355 people, PRP did not significantly improve pain or function compared with placebo at the assessed follow-up points, extending to around six months.
Both results can be true. A relative advantage over steroid does not prove a clinically useful effect beyond placebo. Tennis elbow should not be presented as a condition for which PRP has uniformly strong evidence.
Achilles and patellar tendinopathy: avoid a general tendon promise
A 2026 Achilles review included four placebo-controlled trials involving 337 people. It found no significant benefit for function at three or six months, and no significant benefit in the pooled pain or imaging measures examined.
For patellar tendinopathy, a randomised trial involving 57 people compared one leukocyte-rich PRP injection, one leukocyte-poor PRP injection and saline, followed by supervised rehabilitation. Neither PRP preparation was more effective than saline for the symptoms measured. A single trial does not settle every possible protocol, but it does not support describing patellar PRP as reliably effective.
NICE guidance on autologous blood injection for tendinopathy, whose procedure description includes PRP, states that efficacy evidence remains inadequate. It recommends special arrangements for clinical governance, consent and audit or research. The uncertainty belongs in the treatment discussion, together with appropriate rehabilitation and other options.
Talk through treatment options and their limits or email team@thewellnesslondon.com.
Plantar fasciitis: some medium-term benefit over steroid
A 2025 meta-analysis of 24 randomised trials involving 1,653 people found better pain scores with PRP than corticosteroid at three and six months, but not at one or twelve months. Functional scores favoured PRP at some follow-up points.
That is evidence about a particular comparison and time frame. It should not become a promise of permanent recovery, proof of tissue regeneration or a reason to bypass suitable non-injection care.
Knee osteoarthritis: mixed findings and specific NICE conditions
The RESTORE trial in JAMA enrolled 288 adults with mild-to-moderate knee osteoarthritis. At twelve months, three weekly PRP injections did not significantly improve the main pain or cartilage-volume outcomes compared with saline.
Some pooled analyses report benefits. A 2025 placebo-controlled meta-analysis found clinically relevant functional improvement at the follow-up points studied and pain benefit at three and six months. Another 2025 review found a weak pain effect at three and six months, with debatable clinical relevance, and not at twelve months. The reviews overlap and their participant totals should not be added together.
NICE guidance for knee PRP says effectiveness evidence is limited in quality and recommends special governance, consent and audit or research arrangements. PRP is not established as a treatment that regrows cartilage or prevents knee replacement.
The wider NICE osteoarthritis guideline places tailored therapeutic exercise and weight management, when appropriate, at the centre of care. A simple ranking of injection studies does not replace that plan.
Hip osteoarthritis: improvement after treatment is not enough
A review of recent hip osteoarthritis trials found variable protocols and inconsistent longer-term findings. In its placebo-controlled trial, PRP did not produce greater improvement than saline in pain, function or quality of life over six months.
Hip findings should not be inferred from knee studies. The diagnosis, treatment alternatives and limits of the evidence need their own discussion. Improvement within a PRP group does not establish superiority to an appropriate control.
Facial rejuvenation: promising findings are not a uniform result
A 2025 systematic review of PRP and PRF for facial rejuvenation included twenty studies involving 514 people. Findings were more encouraging for skin thickness and elasticity than for hydration, with mixed results for other concerns.
The review included different study designs and both PRP and PRF. It cannot supply one reliable success percentage for every PRP facial, or establish that injection and microneedling have the same effect. The proposed procedure and the concern being treated need to stay clear.
Safety and a considered treatment plan
Using a person's own blood does not make an injection risk-free. Pain, bruising, swelling, bleeding and infection still need discussion. NICE's statement that evidence raises no major safety concerns is not a claim that complications cannot occur or that every technique is equivalent.
A useful plan brings together the diagnosis, previous care, relevant medicines, realistic benefits, risks and alternatives. It also explains the preparation, proposed number of sessions, total cost, aftercare and review point. More injections or a higher price do not themselves establish a better result.
An enquiry can begin with what has changed and what improvement would matter in daily life. Further assessment, established non-injection treatment or referral may be the right next step. A procedure is not the only useful outcome.
Enquire about an evidence-led assessment or email team@thewellnesslondon.com.
Frequently asked questions
Does PRP actually work?
It depends on the diagnosis, preparation, comparison and outcome. Evidence supports increased hair density in pattern hair loss compared with placebo, while findings for joints, tendons and facial concerns differ. No single success rate applies to every use.
Is PRP proven for tennis elbow?
It should not be described as uniformly proven. Some comparisons favour PRP over steroid for longer-term pain, but a 2026 review of six placebo-controlled trials found no significant pain or functional benefit over placebo at the follow-up points examined.
Does PRP regrow cartilage?
PRP is not established as a cartilage-regrowing or disease-modifying treatment for osteoarthritis. Feeling better after an injection does not prove structural repair or that knee replacement will be avoided.
Do more hair PRP sessions guarantee better results?
No. The cited 2025 hair review did not find a significant association between treatment frequency and the hair-density effect. A proposed schedule needs a clear purpose and review point, not a promise that more is always better.
Why do PRP studies disagree?
Preparations, diagnoses, study methods, comparison treatments and follow-up periods vary. Statistical differences may also be too small to matter clinically. A result against steroid does not answer the same question as a result against placebo.
Is PRP risk-free because it uses my blood?
No. Pain, bruising, swelling, bleeding and infection remain possible. The proposed procedure, relevant health conditions, medicines and aftercare need individual discussion.
Discuss your next step with the clinic or email team@thewellnesslondon.com.
General information, not individual medical advice. Updated 15 November 2026.